Definitive Contract HHSN272201600035C

Award Date 8/30/16
Potential Completion Date 8/30/18
Potential Value $450K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Luis Obispo, CA 93407, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
11
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...
This federal contract award, valued at $16,731,358.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute. The contract is for the continued development of vaccine candidates for biodefense, antimicrobial resistance, emerging infectious diseases, and respiratory pathogens. No set-aside designation was used. AAHI has subcontracted with several institutions, including Emory...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a $49,946.10 firm-fixed-price purchase order contract for antibody expression services to Biointron Biological USA Inc., a small disadvantaged business. The contract, which has no set-aside designation, has an ultimate completion date of July 11, 2025. The award was made on July 12, 2024. NIAID is responsible for conducting and supporting research to understand, treat, and prevent infectious and...
This is a $18,576,013.05 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the nonprofit research institute Access To Advanced Health Institute (AAHI), also known as Aahi, Idri, and Infectious Disease Research Institute. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant (AMR) infections, and emerging infectious...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $600,000 firm-fixed-price definitive contract to Integral Molecular Inc., a small business biotechnology company, for "ADJUVANT TARGET DISCOVERY FOR VACCINES AND FOR AUTOIMMUNE AND ALLERGIC DISEASES." The contract has a completion date of June 29, 2024. Integral Molecular specializes in membrane protein research and has received numerous federal contracts and grants from agencies like the National Institutes of...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL), a leading contract research and manufacturing organization. The $548,977.00 cost-plus-fixed-fee contract is for the delivery of services in support of NIAID's infectious disease research and product development initiatives. This award is a task order under an existing Indefinite...
This is a $598,808 firm fixed price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Inimmune Corp. The contract is for research on adjuvant discovery for vaccines and for autoimmune and allergic diseases. Inimmune Corp is a biotechnology company with expertise in synthetic chemistry, drug formulation, and pharmaceutical manufacturing. They have received...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $375,000 firm fixed price purchase order to Advanced Bioadjuvants, LLC of Omaha, Nebraska. The three-year contract, running from September 2021 through September 2024, provides a non-exclusive license to Advanced Bioadjuvants' Adjuplex adjuvant technology. This will allow the National Institute of Allergy and Infectious Diseases to manufacture cGMP grade...
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services. The contract, valued at $12,763.00, was awarded to Advanced Biotechnologies, Inc. (ABI) on September 19, 2014 for the provision of biomaterial. The contract has a firm fixed price and was not set aside for any specific category of business. The place of performance is Columbia, Maryland. The contract has an ultimate...
This is a delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the Access To Advanced Health Institute (AAHI), a nonprofit biotech research institute. The contract is for in vitro assessment services under the In Vitro Antimicrobial Assessments IDIQ contract, which runs from 2011 to 2018. The contract has a ceiling value of $522,000.00 and was awarded on a firm fixed price basis. The place of...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $449,984 firm fixed-price contract to Applied Biotechnology Institute Inc., a veteran-owned small business, to develop a mucosal prophylactic vaccine against coccidioidomycosis. The contract, with a completion date of August 30, 2018, is a direct result of NIAID's research efforts in the area of allergy and infectious diseases. Applied Biotechnology Institute Inc. has previously received federal grants from NIAID and the U.S. Department of Agriculture to advance its work on plant-based vaccine production and oral delivery systems for various animal and human applications. This contract award is set aside for small businesses.

Generated 4/2/25, 9:13 PM